GlassScriptPhysician profile
Devon Shea Mcintosh
NPI 1790204758
$5,696.71
in general payments reported to CMS, 2019-2025
25 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $832 · 2022: $1,553 · 2023: $1,587 · 2024: $802 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,311.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,250.32 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $902.51 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $652.64 | 2021-2024 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $588.65 | 2021-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $500.81 | 2024-2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $212.59 | 2022-2023 | Stelara, Simponi Aria, Simponi |
| Celgene Corporation | $206.36 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $203.26 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $139.28 | 2021-2023 | Sucraid |
| Vivus LLC | $138.15 | 2023-2025 | Qsymia, Pancreaze |
| Lilly USA, LLC | $136.64 | 2024 | Omvoh |
| Genzyme Corporation | $128.02 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $98.72 | 2021-2024 | Linzess |
| Daiichi Sankyo INC. | $93.95 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $89.82 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.44 | 2023-2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $48.32 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $45.52 | 2023 | Sutab |
| Redhill Biopharma INC. | $39.63 | 2022-2023 | Talicia |
| Intra-Sana Laboratories | $39.21 | 2021 | |
| Ferring Pharmaceuticals INC. | $35.62 | 2022 | |
| Intercept Pharmaceuticals, INC. | $31.61 | 2021-2022 | |
| Celltrion USA INC. | $23.64 | 2024 | Zymfentra |
| Pfizer INC. | $20.17 | 2022 | |
| Alfasigma USA, INC. | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Mcintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.